13F Insight
DOSSIER · 13F-HR · Q2 2026

DCVC Opportunity Fund II GP, LLC

$17M in tracked AUM across 2 positions as of Q2 2026.

DO
CIK 0001668343 · last filed Jun 30, 2026
Total AUM
$17M
as of Q2 2026
Holdings
2
—
positions
Whale Score
63
63
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

DCVC Opportunity Fund II GP, LLC reported a dramatically smaller 13F portfolio as of 2025-09-30: total equity holdings of $19.28 million across a single public holding. This represents an absolute decline of $95.97 million from the prior quarter’s $115.25 million, a drop of 83.3%. The portfolio is extremely concentrated (one holding) and materially smaller in reported long-equity exposure than in the prior quarter.

Key quantified points:

  • Total portfolio value: $19.28M (...

Key Holdings

The sole reported holding is Recursion Pharmaceuticals, Inc. (ticker RXRX, Healthcare):

  • Market value: $19.28M
  • Shares held: 3.95M
  • Implied average price in the filing: approximately $4.88 per share (19.28M / 3.95M)

RXRX comprises 100.0% of the fund’s disclosed 13F portfolio value. The filing marks RXRX as unchanged versus the prior quarter (i.e., the reported position was carried forward rather than increased or newly opened on this 13F). Because the entire reported portfolio is concentrated in one issuer, the filer’s public-equity exposure is fully exposed to RXRX-specific price and company developments.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
RXRX
Recursion Pharmaceuticals, Inc.
$15M4.0M84.3%02
IONQ
IonQ, Inc.
$3M51K15.7%

Filing history

2026Q2Jun 30
$17M▲ 3.7%
2 positionsView →2025Q4Dec 31
$17M▼ 14.0%
2 positionsView →2025Q3Sep 30
$19M▼ 83.3%
1 positionsView →2025Q2Jun 30
$115M▲ 451.4%
2 positionsLocked2025Q1Mar 31
$21M▼ 81.5%
1 positionsLocked2024Q4Dec 31
$113M▲ 16.1%
2 positionsLocked2024Q3Sep 30
$97M▲ 47.7%
3 positionsLocked2024Q2Jun 30
$66M▼ 7.7%
3 positionsLocked2024Q1Mar 31
$71M▼ 11.6%
3 positionsLocked2023Q4Dec 31
$81M▲ 4.6%
4 positionsLocked2022Q3Sep 30
$77M▲ 13.8%
5 positionsLocked2022Q2Jun 30
$68M▼ 24.2%
5 positionsLocked
Showing 12 of 14